All In Biotech

Drug Trial Radar · NCT04322617

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Mar 24, 2020

Primary completion

Mar 24, 2028

Study completion Mar 24, 2029

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Anlotinib plus the same Immune Checkpoint Inhibitors.Drug

    Anlotinib, 8mg po qd, D1-D14 every 21days.

  • Anlotinib plus the new Immune Checkpoint Inhibitors.Drug

    Anlotinib, 8mg po qd, D1-D14 every 21days.

  • AnlotinibDrug

    Anlotinib, 8mg po qd, D1-D14 every 21days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival time (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongchang Zhang

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.